More Leaks in the Dam: Who's the New Whistleblower on Avandia?
This article was originally published in RPM Report
The Senate Finance Committee loves FDA whistleblowers. And it sounds like they have found another one as part of their investigation of the review of GlaxoSmithKline PLC’s diabetes drug rosiglitazone (Avandia).
You may also be interested in...
Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.
The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.